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Background: All types of membranoproliferative glomerulonephritis (MPGN) are
progressive diseases with poor prognoses. Recently, a newly proposed classiﬁcation
of these diseases separated them into immune complex- and complement-
mediated diseases. We investigated the frequency of C3 glomerulonephritis among
previously diagnosed MPGN patients.
Methods: We conducted a retrospective study of patients diagnosed with MPGN at
three tertiary care institutions between 2001 and 2010. We investigated the
incidence of complement-mediated disease among patients diagnosed with MPGN.
Progressive renal dysfunction was deﬁned as a 50% reduction in the glomerular
ﬁltration rate or the need for renal replacement therapy.
Results: Among the 3,294 renal biopsy patients, 77 (2.3%) were diagnosed with MPGN;
31 cases were excluded, of which seven were diagnosed with systemic lupus nephritis,
and the others were not followed for a minimum of 12 months after biopsy. Based on
the new classiﬁcation, complement-mediated MPGN was diagnosed in two patients
(4.3%); only one patient developed progressive renal dysfunction. Among the immune
complex-mediated MPGN patients, 17 patients developed progressive renal dysfunction.
Serum albumin and creatinine levels at the time of MPGN diagnosis were risk factors of
renal deterioration, after adjusting for low C3 levels and nephrotic syndrome.
Conclusion: Complement-mediated glomerulonephritis was present in 4.3% of patients
previously diagnosed with MPGN.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).n Society of Nephrology. Publi
c-nd/4.0/).
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Membranoproliferative glomerulonephritis (MPGN) describes a
general pattern of glomerular injury seen in a variety of disease
processes sharing a common pathogenic mechanism rather than a
single disease entity. Primary MPGN was previously classiﬁed
according to its histopathological pattern (types I, II, and III),
based on the ultrastructural location of electron dense deposits.shed by Elsevier. This is an open access article under the CC BY-NC-ND
Table 1. Patient characteristics at the time of renal biopsy
Characteristics
Age (y) 45.9 (18–84)
Sex (M/F) 28/18
LM classiﬁcation
Type I/type III 28/18 (60.8/39.1)
IF classiﬁcation
Immune mediated/complement mediated 44/2 (95.7/4.3)
HBs antigenemia 17 (37.7)
Hypertension 19 (41)
Creatinine (mg/dL) 1.2570.95
GFR (mL/min) 61.24741.89
Hematurian 38 (84.4)
Urine protein (mg/24 h) 4,644.5874,521.98
Nephrotic syndrome† 21 (45.6)
Albumin (g/dL) 2.9470.78
Decreased C3‡ 13 (28)
nZ3 red blood cells/high power ﬁeld.
† Proteinuria Z3.5 g/day and serum albumin o3.0 g/dL.
‡ Serum C3o65 mg/dL.
Data are presented as n (%) or mean7SD, unless otherwise indicated.
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pathogenesis of MPGN has led to a paradigm shift in the disease
classiﬁcation. The proposed reclassiﬁcation of MPGN into
immunoglobulin-mediated disease via activation of the classical
complement pathway, versus nonimmunoglobulin-mediated dis-
ease via activation of the alternative complement pathway (AP),
has led to improved diagnostic algorithms and the emergence of a
new disease category called C3 glomerulonephritis (C3GN) [1].
Improved understanding of MPGN, particularly the focus on the
activity of the AP in C3GN, will lead to improved disease outcomes
[2]. However, the frequency of C3GN remains unknown among
patients previously diagnosed with MPGN. MPGN patients typi-
cally demonstrate poor renal outcomes, with a reported 10-year
renal survival rate of approximately 40%. Prognoses according to
the new classiﬁcation, however, are unknown; studies on two
cohorts have shown that C3GN is not a benign disease [3,4].
We conducted a multicenter reanalysis of a 10-year renal
biopsy registry, to investigate the incidence and long-term
outcomes of C3GN among MPGN patients.F, female; GFR, glomerular ﬁltration rate; HBs, hepatitis B surface
antibody; IF, immunoﬂuorescence; LM, light microscopy; M, male; SD,
standard deviation.Methods
Patients
We collected retrospective clinical data on patients diag-
nosed with MPGN, based on renal biopsy ﬁndings at three
tertiary care institutions (Soonchunhyang University, Seoul,
Korea, Bucheon Hospital, Bucheon, Korea, and Cheonan Hos-
pital, Cheonan, Korea), between 2001 and 2010. Patients who
were followed for 412 months were included in the study.
Patients diagnosed with lupus nephritis were excluded.
We investigated the following results (collected at the time
of diagnosis): complete blood counts; renal function tests;
liver function tests; urine analyses; and levels of serum C3,
serum C4, immunoglobulin G, serum albumin, serum hepatitis
B surface antigens (HBsAg), anti-hepatitis B surface antibody,
and anti-hepatitis C antibody (HCV Ab). All renal biopsy
specimens were examined by a pathologist using light, immu-
noﬂuorescence, and electron microscopy at the time of the
initial biopsy. We reviewed the pathologic ﬁndings and reclas-
siﬁed the patients as having immunoglobulin-mediated MPGN
when immunoglobulin and complement were evident on
immunoﬂuorescent microscopy or as having complement-
mediated MPGN when marked immunoglobulin staining was
not observed by immunoﬂuorescent microscopy.
The diagnosis of type I or III MPGN was based on the
presence of a kidney disorder characterized by mesangial cell
proliferation and structural changes in the glomerular capillary
walls [5]. C3 glomerulonephritis was deﬁned by the presence
of glomerular C3 staining, in the absence of immunoglobulin,
together with electron-dense subendothelial glomerular base-
ment membranes and mesangial deposits [4,5].
Hypertension was diagnosed if the patient had a systolic
blood pressure (BP) of Z140 mmHg and/or diastolic BP of
Z90 mmHg or was prescribed antihypertensive medication(s).
Microscopic hematuria was deﬁned as Z3 red blood cells/high
power ﬁeld. Nephrotic syndrome was deﬁned based on the
presence of proteinuria (Z3.5 g/d) and hypoalbuminemia
(serum albumin o3.0 g/dL). The glomerular ﬁltration rate
(GFR) was estimated using the Chronic Kidney Disease Epide-
miology Collaboration equation [6]. Renal impairment at the
time of the biopsy was deﬁned as a GFR of o60 mL/min atdiagnosis. Progressive renal dysfunction was deﬁned as a 50%
reduction in the estimated GFR (eGFR) or the need for renal
replacement therapy during the follow-up period. Stable renal
function was deﬁned as renal function maintained at o50%
reduction in eGFR during the follow-up period.
Statistical analysis
Statistical analyses were performed with SPSS version 14.0
(SPSS Inc., Chicago, IL, USA). Data were expressed as
mean7standard deviation. Results yielding Po0.05 were con-
sidered statistically signiﬁcant. Signiﬁcant differences between
groups were determined using independent t tests. Categorical
variables were compared using either the Pearson's Chi-square
test or Fisher's exact test. Multiple logistic regression analysis was
performed to identify the independent risk factors for renal death
among the parameters selected through univariate analysis.Results
Among the 3,294 patients undergoing renal biopsy during
the study period, 77 (2.3%) were diagnosed with MPGN.
Thirty-one cases were excluded because seven patients were
diagnosed with systemic lupus erythematosus, and the others
were not followed up for the required 12 months after biopsy;
thus, 46 cases were eligible for analysis. Lupus nephritis was
excluded because the prognosis was different. The clinical
manifestations, at the time of the renal biopsy, are shown in
Table 1. For the 46 included patients (males, 28; females, 18),
the mean age was 45 years and the mean eGFR was 61.2741.9
mL/min. Thirty-eight patients (84.4%) had hematuria, and 20
patients (45.6%) had nephrotic syndrome. Over a mean follow-
up period of 82.8 months, 17 patients (39.6%) developed
progressive renal dysfunction, of which nine patients (19.6%)
required renal replacement therapy.
According to the classical pathologic classiﬁcation, 28
patients (60.8%) were classiﬁed with MPGN type I, and 18
patients (39.2%) were classiﬁed with MPGN type III. Following
the new classiﬁcation, immune-mediated MPGN was observed
Table 2. Clinicolaboratory ﬁndings between patients with stable renal function and those with progressive renal dysfunction
Characteristics Stable renal function (n¼28) Progressive renal dysfunction (n¼16) P
Age (y) 44.6 (23–72) 47.9 (18–84) 0.547
Sex (M/F) 15/13 13/3 0.066
HBs antigenemia 9 (32) 8 (50) 0.280
Systolic blood pressure (mmHg) 131.43720.31 140.33722.56 0.213
Diastolic blood pressure (mmHg) 80.7179.79 90.00714.64 0.017
Creatinine (mg/dL) 0.9470.41 1.8271.37 0.023
Glomerular ﬁltration rate 97.7737.65 61.33733.04 0.003
Hematurian 24 (85.7) 13 (86.7) 0.932
Urine protein (mg/24 h) 4,332.2574,391.90 5,545.4474,926.23 0.404
Nephrotic syndrome 11 (39.3) 9 (56.3) 0.227
Albumin (g/dL) 3.1770.73 2.4770.63 0.003
C3 (mg/dL)† 81.98729.40 62.08724.04 0.029
C4 (mg/dL)‡ 19.8179.27 21.26713.02 0.680
CH50 (U/mL)
§ 27.73710.78 23.7379.91 0.528
IgG (mg/dL)¶ 875.877298.39 1,070.897973.66 0.478
nZ3 red blood cells/high power ﬁeld.
† C3 reference range, 65–135 mg/dL.
‡ C4 reference range, 13–35 mg/dL.
§ CH50 (50% hemolytic unit of complement reference range, 23–46.
¶ IgG reference range, 870–1,700 mg/dL.
Data are presented as n (%) or mean7SD, unless otherwise indicated.
F, female; HBs, hepatitis B surface antibody; IgG, immunoglobulin G; M, male; SD, standard deviation.
Table 3. Possible predictive risk factors of progressive renal
dysfunction
Odds ratio 95% conﬁdence interval P
Nephrotic syndrome 0.293 0.040–2.121 0.224
Serum albumin 0.170 0.037–0.775 0.022
Serum creatinine 9.161 1.024–81.920 0.048
Low complement 3
(C3o65 mg/dL)
2.665 0.427–16.627 0.294
Figure 1. The renal survival curve during long-term follow-up. The
initial glomeruloﬁltration rate is an important prognostic factor for
membranoproliferative glomerulonephritis patients (Kaplan–Meier).
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with complement-mediated MPGN, both of whom had C3GN.
One C3GN patient developed end-stage renal disease within
23 months from the time of biopsy. Renal impairment (eGFR,
41 mL/min), hypoalbuminemia (2.4 g/dL), nephrotic syndrome,
and hypertension were observed at the time of the biopsy in
this case. The other C3GN patient maintained renal function
during the follow-up period (41 months). This individual
displayed normal kidney function (eGFR, 99 mL/min), normal
BP, and mild proteinuria (urine protein, 471 mg/24 h) at the
time of the biopsy.
According to the classic pathologic classiﬁcation, among the
patients with immune complex-mediated MPGN, 27 (61.4%)
had MPGN type I and 17 (38.6%) had MPGN type III. Of the 27
type I and 17 type III patients, 11 (41%) and ﬁve (29%),
respectively, developed progressive renal dysfunction. However,
there was no signiﬁcant difference in the incidence of progres-
sive renal dysfunction between the two types (P¼0.447).
Among the patients with immune complex mediated MPGN,
15 had positive HBsAg, one had HBsAg positive with HCV Ab
positive, and one had cancer at diagnosis.
We additionally divided the patients with immune
complex-mediated MPGN into those with stable renal function
and those with progressive renal dysfunction. The clinical and
laboratory parameters of the two groups are compared in
Table 2. Renal function, at diagnosis, was impaired to a greater
extent in patients with progressive renal dysfunction (serum
creatinine, P¼0.023; eGFR, P¼0.003), and they had signiﬁ-
cantly lower serum albumin and C3 levels, than those in the
stable renal function group. There were no signiﬁcant differ-
ences in hepatitis B surface antibody levels, antigenemia,
hematuria, or proteinuria between the two groups. We also
analyzed the prognostic factors that inﬂuenced renal outcome.
According to the univariate analysis, serum albumin and
creatinine levels at diagnosis, and GFR were signiﬁcant risk
factors, whereas sex, hypertension, nephrotic syndrome, low
C3 levels, and age were not. Serum albumin and creatinine
levels, at diagnosis, remained signiﬁcant risk factors after
adjusting for complement levels and the presence of nephrotic
syndrome (Table 3).Renal survival rate was decreased in patients with renal
impairment at the time of the biopsy, compared with those
without renal impairment (P¼0.001; Fig. 1). All patients
Kidney Res Clin Pract 33 (2014) 187–191190received renin–angiotensin system inhibitors, and 16 patients
were also treated with immunosuppressants. Among those
treated with immunosuppressants, ﬁve patients experienced
an overall 50% reduction in eGFR. Six patients died during the
follow-up period owing to cancer (4 patients) or hepatorenal
syndrome with hepatocellular carcinoma or liver cirrhosis (2
patients). Cancer was diagnosed in six patients; one patient
had stomach cancer at the time of renal biopsy, and the others
developed cancer (stomach cancer, 1 patient; rectal cancer,
1 patient; lung cancer, 1 patient; hepatocellular carcinoma,
2 patients) during the follow-up period.Discussion
Our study showed that the incidence of C3GN was 4.3%
among patients with previously diagnosed MPGN who were
followed up for 412 months. The incidence of C3GN among
MPGN patients has not been reported previously. MPGN is a
rare disease that leads to an extremely rare incidence of C3GN.
The concept of C3GN was ﬁrst introduced in 2007 when
Servais et al [7] characterized a group of patients with isolated
C3 deposits, previously referred to as proliferative glomerulo-
nephritis with C3 deposits. Some glomerulonephrites may
appear because of dysregulation of the AP. Mutations or
antibodies against multiple complement regulators and inhi-
bitors that prevent self-mediated damage can alter the control
of the AP and lead to the development of MPGN [1,7,8]. C3GN
is characterized by prominent glomerular C3 deposition, with-
out signiﬁcant immunoglobulin deposits evident on immuno-
ﬂuorescent microscopy. Complement proteins from the AP and
terminal complement complexes, as well as complement
regulating proteins, were found in the glomeruli of C3GN
patients. Proteins of the classic pathway, such as C1 and C4,
were not present in patients with C3GN [3].
A better understanding of the disease pathogenesis has led
to newly proposed assessment and treatment methods.
Recently, newer drugs, such as the anti-C5 monoclonal anti-
body, eculizumab, have been suggested for treating
complement-mediated MPGN [9–11]. Bomback et al [12]
reported that eculizumab improved the clinical and histo-
pathologic ﬁndings in C3GN patients. Three patients with
C3GN were treated with eculizumab for 53 weeks. Some
patients showed improved renal function, and normalization
of elevated levels of soluble membrane attack complexes.
Conversely, some patients showed declining renal function
during treatment [12]. Elevation of soluble membrane attack
complex (C5b-9) levels, an indicator of the activation of the
terminal complement cascade, is predictive of a response to
eculizumab treatment [10,12]. The patient in our study had
poor prognostic factors, including renal impairment, and
showed poor renal outcomes. During the follow-up period,
the patient received only renin–angiotensin system blockers
and progressed to end-stage renal disease. The effectiveness of
nonspeciﬁc immunomodulatory therapy is controversial
[13,14]. Therefore, eculizumab may be a treatment option for
C3GN patients with poor prognostic factors.
The disease prognosis of the recently described C3GN
remains largely unknown. Very few studies have described
the clinical features of C3GN. Two C3GN patients in one study
maintained their renal function [8]. Another study described
the renal outcomes of 12 patients with C3GN, including two
patients undergoing allograft transplantation. Among the 12patients, two developed progressive renal dysfunction (50%
reduction of eGFR or the need for renal replacement therapy)
and both developed recurrent disease following allograft
transplantation [4]. C3GN had a very low prevalence (4.3%)
among the MPGN patients in our study. Complement analysis
was not performed, because the pathogenesis of C3GN was
unknown at the time of biopsy. The number of patients with
C3GN was too small to represent the overall renal outcomes
for patients with the disease. One of the two C3GN patients, in
this study, progressed to renal dysfunction. This patient had
high classical risk factors. Further study should reveal the
prognostic factors related to disease pathogenesis.
Classical signs of nephrotic syndrome, elevated serum
creatinine levels, hypertension, and crescents on renal biopsy
are indicative of poor prognosis upon presentation with MPGN
[15–17]. Our data were very similar to those described in
previous studies. Future studies are required to identify the
different prognostic factors relevant to both immune-
mediated MPGN and C3GN. Further studies should also clarify
the features and prognosis factors in immune-mediated MPGN
excluding C3GN, because previous studies did not exclude
C3GN among the MPGN population.
Our study has several limitations. First, this study was
retrospective. Second, we did not evaluate the abnormalities
of the alternative pathway because these laboratory data were
not routinely investigated. Third, only a very small number of
C3GN patients were available for inclusion; hence, the prog-
nostic factors were not fully evaluated. However, our study
showed the incidence of C3GN and the individual factors
involved in the prognosis of C3GN.
In conclusion, C3GN occurred at a rate of 4.3% among
patients previously diagnosed with MPGN. Initial GFR was an
important prognosis factor in immune-mediated MPGN.
Further studies involving more patients and longer follow-up
periods are necessary to conclusively determine the disease
prognosis and the usefulness of anticomplement therapy
in C3GN.Conﬂict of interest
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